Aptose Biosciences Inc. (NASDAQ: APTO) shares have exhibited a remarkable ascent, making a 12.77% increase, closing at $3.18 on Friday in the regular trading. This surge in Aptose Biosciences’ stock this session value is attributed to the impending release of a clinical update scheduled for Monday, October 30, 2023.
The forthcoming clinical update from APTO will coincide with poster presentations at the esteemed European School of Haematology (ESH) 6th International Conference, taking place from October 29 to 31, 2023, in the picturesque locale of Estoril, Portugal. The featured poster is entitled “Acute Myeloid Leukemia: Molecular and Translational Advances in Biology and Treatment.”
This webcast event promises a comprehensive overview of the most recent clinical data pertaining to Aptose’s lead compound, tuspetinib. Notably, it will showcase the insights of Dr. Naval Daver, MD, who holds the position of Professor and is the Director of the Leukemia Research Alliance Program within the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, TX.
Dr. Daver serves as the principal investigator for Aptose’s APTIVATE trial and has gained recognition for his substantial contributions to the development of innovative treatments for acute myeloid leukemia (AML), including various combination therapies. Tuspetinib, when administered as a monotherapy, has demonstrated a commendable level of tolerability and remarkable efficacy in a diverse group of patients afflicted with relapsed or refractory (R/R) AML.
Impressively, it yielded a 42% complete response or complete response with partial hematologic recovery (CR/CRh) rate among assessable patients who had not previously been exposed to venetoclax (VEN). Furthermore, the APTIVATE international Phase 1/2 expansion trial is currently investigating the combination of tuspetinib with venetoclax (VEN) in R/R AML patients.
This combination, known as the TUS/VEN doublet, has been well-tolerated and has delivered multiple positive responses in patients who had previously failed venetoclax, including those who had experienced prior failures with FLT3 inhibitors. This patient cohort represents an emerging demographic with substantial unmet medical needs.
Aptose Biosciences is also scheduled to release its financial results for the third quarter ending on September 30, 2023, for Thursday, November 9, 2023, after the close of the market. This announcement will be accompanied by a corporate update.
